CpG-motifs enhance initial and sustained primary tetanus-specific antibody secreting cell responses in spleen and bone marrow, but are more effective in adult than in neonatal mice

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2492-2499

  Pihlgren, Maria ^a   Tougne, Chantal ^a   Schallert, Nadine ^a   Bozzotti, Paola ^a   Lambert, Paul Henri ^a   Siegrist, Claire Anne ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antibodies; CpG motifs; Neonatal

Indexed keywords

ADJUVANT; ANTIGEN; OLIGONUCLEOTIDE; TETANUS TOXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW; CELL SECRETION; COMPARATIVE STUDY; CONTROLLED STUDY; CPG ISLAND; EXPERIMENTAL MODEL; GERMINAL CENTER; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; SPLEEN; TETANUS PROPHYLAXIS;

EID: 0038402751     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00052-5     Document Type: Article

References (35)

1. Krieg A.M. Immune effects and mechanisms of action of CpG-motifs. Vaccine. 19(6):2000;618-622.
2. Krieg A.M., Yi A.K. Rescue of B cells from apoptosis by immune stimulatory CpG DNA. Springer Semin. Immunopathol. 22(1-2):2000;55-61.
3. Yi A.K., Peckham D.W., Ashman R.F., Krieg A.M. CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int. Immunol. 11(12):1999;2015-2024.
4. Yi A.K., Chang M., Peckham D.W., Krieg A.M., Ashman R.F. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 160(12):1998;5898-5906.
5. L. J. Immunol. 157(11):1996;4918-4925.
6. Jahrsdorfer B., Hartmann G., Racila E.et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukoc. Biol. 69(1):2001;81-88.
7. Krieg A.M., Yi A.K., Matson S.et al. CpG-motifs in bacterial DNA trigger direct B-cell activation. Nature. 374(6522):1995;546-549.
8. Klinman D.M., Barnhart K.M., Conover J. CpG-motifs as immune adjuvants. Vaccine. 17(1):1999;19-25.
9. Krieg A.M., Davis H.L. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3(1):2001;15-24.
10. Davis HL, Cooper CL, Morris ML, Elfer SM, Cameron DW, Heathcote J. CpG-ODN is safe and highly effective in humans as adjuvant to HBV vaccine: preliminary results of Phase I trial with CpG-ODN 7909. In: Proceedings of the Third Annual Conference on Vaccine Research. Washington, DC. 2000.
11. Brazolot Millan C.L., Weeratna R., Krieg A.M., Siegrist C.A., Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. U.S.A. 95(26):1998;15553-15558.
12. Kovarik J., Bozzotti P., Love-Homan L.et al. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 162(3):1999;1611-1617.
13. Kovarik J., Bozzotti P., Tougne C.et al. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology. 102(1):2001;67-76.
14. Hartmann G., Weeratna R.D., Ballas Z.K.et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164(3):2000;1617-1624.
15. Davis H.L., Weeratna R., Waldschmidt T.J.et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160(2):1998;870-876.
16. Pihlgren M., Schallert N., Tougne C.et al. Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur. J. Immunol. 31(3):2001;939-946.
17. Siegrist C. Neonatal and early life vaccinology. Vaccine. 19(25/26):2001;3331-3346.
18. Barrios C., Brawand P., Berney M., Brandt C., Lambert P.H., Siegrist C.A. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur. J. Immunol. 26(7):1996;1489-1496.
19. Slifka M.K., Matloubian M., Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. J. Virol. 69(3):1995;1895-1902.
20. Macdonald R.A., Hosking C.S., Jones C.L. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods. 106(2):1988;191-194.
21. Goldblatt D., Simple solid phase assays of avidity. In: Turner MW, Johnstone AP, editors. Immunochemistry 2: a practical approach. Oxford: IRL Press; 1997. p. 31-51.
22. McCloskey N., Turner M.W., Goldblatt T.D. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). J. Immunol. Methods. 205(1):1997;67-72.
23. Goldblatt D., Vaz A.R., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177(4):1998;1112-1115.
24. Schallert N., Pihlgren M., Kovarik J.et al. Generation of adult-like antibody avidity profiles after early-life immunization with protein vaccines. Eur. J. Immunol. 32(3):2002;752-760.
25. Takahashi Y., Dutta P.R., Cerasoli D.M., Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. J. Exp. Med. 187(6):1998;885-895.
26. Slifka M.K., Antia R., Whitmire J.K., Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 8(3):1998;363-372.
27. Smith K.G., Weiss U., Rajewsky K., Nossal G.J., Tarlinton D.M. Bcl-2 increases memory B cell recruitment but does not perturb selection in germinal centers. Immunity. 1(9):1994;803-813.
28. Strasser A., Whittingham S., Vaux D.L.et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. U.S.A. 88(19):1991;8661-8665.
29. Smith K.G., Hewitson T.D., Nossal G.J., Tarlinton D.M. The phenotype and fate of the antibody-forming cells of the splenic foci. Eur. J. Immunol. 26(2):1996;444-448.
30. Smith K.G., Light A., O'Reilly L.A., Ang S.M., Strasser A., Tarlinton D. bcl-2 transgene expression inhibits apoptosis in the germinal center and reveals differences in the selection of memory B cells and bone marrow antibody-forming cells. J. Exp. Med. 191(3):2000;475-484.
31. Sze D.M., Toellner K.M., Garcia de Vinuesa C., Taylor D.R., MacLennan I.C. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J. Exp. Med. 192(6):2000;813-821.
32. Garcia De Vinuesa C., Gulbranson-Judge A., Khan M.et al. Dendritic cells associated with plasmablast survival. Eur. J. Immunol. 29(11):1999;3712-3721.
33. Lindhout E., Mevissen M.L., Kwekkeboom J., Tager J.M., de Groot C. Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis. Clin. Exp. Immunol. 91(2):1993;330-336.
34. Koopman G., Keehnen R.M., Lindhout E., Zhou D.F., de Groot C., Pals S.T. Germinal center B cells rescued from apoptosis by CD40 ligation or attachment to follicular dendritic cells, but not by engagement of surface immunoglobulin or adhesion receptors, become resistant to CD95-induced apoptosis. Eur. J. Immunol. 27(1):1997;1-7.
35. Merville P., Dechanet J., Desmouliere A.et al. Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J. Exp. Med. 183(1):1996;227-236.